{"id":55206,"date":"2020-07-28T15:32:05","date_gmt":"2020-07-28T15:32:05","guid":{"rendered":"https:\/\/icrowdnewswire.com\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/"},"modified":"2020-07-28T15:32:05","modified_gmt":"2020-07-28T15:32:05","slug":"latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/","title":{"rendered":"Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences"},"content":{"rendered":"

\"\"<\/p>\n

Gilead Sciences, Inc. has announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics Inc., a privately held company developing first-in-class cancer immunotherapies. Gilead will also receive an exclusive option to acquire the remainder of Tizona for up to an additional $1.25 billion, including an option exercise fee and potential future milestone payments.<\/p>\n

Latham & Watkins LLP represents Tizona in the transaction with a corporate deal team led by Bay Area partner Mark Bekheit, with Orange County associate Brett Urig and Bay Area associates Michelle Lu, Raul Gonzalez and Christopher Lim; on general corporate matters by Bay Area partners Judith Hasko and Ben Potter; on intellectual property matters by Bay Area associates Jekkie Kim and Peggy Ni; on benefits and compensation matters by Bay Area partner Ashley Wagner, with Bay Area associate James Robinson; on regulatory matters by Washington, D.C. partner Ben Haas, with associate Nathan Beaton; on healthcare and privacy matters by Bay Area counsel Betty Pang and Heather Deixler; on tax matters by Bay Area partner Kirt Switzer, with New York associate Lauren Bewley; and on antitrust matters by Washington, DC partner Mandy Reeves and counsel Patrick English.<\/p>\n

\n

See Campaign: <\/strong>https:\/\/legaldesire.com\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/<\/a>
Contact Information:<\/b>
Legal Desire<\/p>\n

Tags:<\/b>
<\/a>, Wire<\/a>, United States<\/a>, English<\/a><\/p>\n

\"image\"<\/div>\n

\n

Contact Information:<\/h3>\n

Legal Desire<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

\"\"Gilead Sciences, Inc. has announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics Inc., a privately held company developing first-in-class cancer immunotherapies. Gilead will also receive an exclusive option to acquire the remainder of Tizona for up to an additional $1.25 billion, including an option exercise fee … Continue reading Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences<\/span><\/a> Continue Reading →<\/span><\/a><\/p>\n","protected":false},"author":139,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,22,54],"tags":[],"class_list":["post-55206","post","type-post","status-publish","format-standard","hentry","category-english","category-united-states","category-wire"],"yoast_head":"\nLatham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences - Business\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences, Inc. has announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics Inc., a privately held company developing first-in-class cancer immunotherapies. Gilead will also receive an exclusive option to acquire the remainder of Tizona for up to an additional $1.25 billion, including an option exercise fee … Continue reading Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences Continue Reading →\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-28T15:32:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/06\/4221-imgpsh_fullsize_anim.png\" \/>\n<meta name=\"author\" content=\"bakhtawar\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"bakhtawar\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/\",\"url\":\"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/\",\"name\":\"Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/06\/4221-imgpsh_fullsize_anim.png\",\"datePublished\":\"2020-07-28T15:32:05+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/f0e1acb4900024aed5468747206156d4\"},\"breadcrumb\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/06\/4221-imgpsh_fullsize_anim.png\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/06\/4221-imgpsh_fullsize_anim.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/f0e1acb4900024aed5468747206156d4\",\"name\":\"bakhtawar\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/84eb90ed2dacf47a111d6e2d014c8e24b61ff0d3daa4625d8fee23fc6808222b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/84eb90ed2dacf47a111d6e2d014c8e24b61ff0d3daa4625d8fee23fc6808222b?s=96&d=mm&r=g\",\"caption\":\"bakhtawar\"},\"sameAs\":[\"https:\/\/icrowdnewswire.com\/fc\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/bakhtawar\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/","og_locale":"en_US","og_type":"article","og_title":"Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences - Business","og_description":"Gilead Sciences, Inc. has announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics Inc., a privately held company developing first-in-class cancer immunotherapies. Gilead will also receive an exclusive option to acquire the remainder of Tizona for up to an additional $1.25 billion, including an option exercise fee … Continue reading Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences Continue Reading →","og_url":"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/","og_site_name":"Business","article_published_time":"2020-07-28T15:32:05+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/06\/4221-imgpsh_fullsize_anim.png","type":"","width":"","height":""}],"author":"bakhtawar","twitter_card":"summary_large_image","twitter_misc":{"Written by":"bakhtawar","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/","url":"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/","name":"Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/#primaryimage"},"image":{"@id":"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/06\/4221-imgpsh_fullsize_anim.png","datePublished":"2020-07-28T15:32:05+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/f0e1acb4900024aed5468747206156d4"},"breadcrumb":{"@id":"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/06\/4221-imgpsh_fullsize_anim.png","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/06\/4221-imgpsh_fullsize_anim.png"},{"@type":"BreadcrumbList","@id":"http:\/\/ipsnews.net\/business\/2020\/07\/28\/latham-watkins-advises-tizona-therapeutics-in-acquisition-by-gilead-sciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"Latham & Watkins Advises Tizona Therapeutics in Acquisition by Gilead Sciences"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/f0e1acb4900024aed5468747206156d4","name":"bakhtawar","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/84eb90ed2dacf47a111d6e2d014c8e24b61ff0d3daa4625d8fee23fc6808222b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84eb90ed2dacf47a111d6e2d014c8e24b61ff0d3daa4625d8fee23fc6808222b?s=96&d=mm&r=g","caption":"bakhtawar"},"sameAs":["https:\/\/icrowdnewswire.com\/fc"],"url":"https:\/\/ipsnews.net\/business\/author\/bakhtawar\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/55206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=55206"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/55206\/revisions"}],"predecessor-version":[{"id":55207,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/55206\/revisions\/55207"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=55206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=55206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=55206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}